Abstract

It has been estimated that about 3 in 10 000 people in Britain's cities have systemic lupus erythematosus (SLE)1 and the true figure may be higher.2 Forty years ago, approximately 50% of patients with SLE died within 4 years of diagnosis.3 Prospects have improved with refinements in therapy and the recognition of mild forms of the disease.